Cargando…

Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naïve Patients with HBeAg Positive Chronic Hepatitis B

The authors assessed the efficacy and antiviral resistance of 48-week clevudine therapy versus lamivudine in treatment of naïve patients with HBeAg positive chronic hepatitis B. In this retrospective study, a total of 116 HBeAg positive patients, who received 30 mg of clevudine once daily (n=53) or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, In Hee, Lee, Seok, Kim, Seong Hun, Kim, Sang Wook, Lee, Seung Ok, Lee, Soo Teik, Kim, Dae Ghon, Choi, Chang Soo, Kim, Haak Cheoul
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858834/ https://www.ncbi.nlm.nih.gov/pubmed/20436711 http://dx.doi.org/10.3346/jkms.2010.25.5.738

Ejemplares similares

Mathematical Modeling of Triphasic Viral Dynamics in Patients with HBeAg-Positive Chronic Hepatitis B Showing Response to 24-Week Clevudine Therapy
por: Kim, Hwi Young, et al.
Publicado: (2012)

Long-Term Treatment Efficacy and Safety of Clevudine Therapy in Naïve Patients with Chronic Hepatitis B
por: Choung, Bum Su, et al.
Publicado: (2012)

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
por: Lim, Chee Kent, et al.
Publicado: (2006)

Is the function of the HBeAg really unknown?
por: Milich, David R.
Publicado: (2019)

Efficacy of Initial Treatment with Clevudine in Naive Patients with Chronic Hepatitis B
por: Yang, Hyeon Woong, et al.
Publicado: (2010)

Clevudine Induced Mitochondrial Myopathy
por: Park, Soo-Hyun, et al.
Publicado: (2017)

Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B
por: Zhu, Xiao-Feng, et al.
Publicado: (2011)

Clinical Efficacy of a 24-months Course of Lamivudine Therapy in Patients with HBeAg Negative Chronic Hepatitis B: A Long-term Prospective Study
por: Paik, Yong Han, et al.
Publicado: (2010)

Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B
por: Winther, Thilde Nordmann, et al.
Publicado: (2013)

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
por: Song, Byung-Cheol, et al.
Publicado: (2014)

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients
por: Yang, Jiezuan, et al.
Publicado: (2014)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
por: Kim, Young Jip, et al.
Publicado: (2013)

Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver
por: Bae, Sung Kwan, et al.
Publicado: (2012)

Manifestations of Perihepatic Lymph Nodes in Acute Flare of Chronic Hepatitis B: Association with HBeAg Status and with HBeAg Seroconversion
por: Ko, Yen-Ling, et al.
Publicado: (2015)

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
por: Song, Guangjun, et al.
Publicado: (2023)

Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis
por: Zhao, Pan, et al.
Publicado: (2011)

Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?
por: Chun, Ho Soo, et al.
Publicado: (2021)

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients
por: Yang, Song, et al.
Publicado: (2016)

The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore
por: Lacey, L F, et al.
Publicado: (2007)

Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro
por: Tacke, Frank, et al.
Publicado: (2012)

Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China
por: Chen, Tianyan, et al.
Publicado: (2018)

A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients
por: Tak, Won Young, et al.
Publicado: (2014)

Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B
por: Li, Minghui, et al.
Publicado: (2022)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

Analysis of clinical and virologic features in Hepatitis B e Antigen (HbeAg)-negative and HbeAg-positive Egyptian chronic hepatitis B patients
por: Fouad, Rabab, et al.
Publicado: (2020)

HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
por: Lee, Soon Kyu, et al.
Publicado: (2023)

Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy
por: Zhang, Xu-Qing, et al.
Publicado: (2013)

Viral Biomarkers in Chronic HBeAg Negative HBV Infection
por: Hadziyannis, Emilia, et al.
Publicado: (2018)

Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase
por: Lee, Hye Won, et al.
Publicado: (2020)

Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels
por: Shi, Hong, et al.
Publicado: (2017)

Efficacy of peginterferon α-2a and predictors of response in HBeAg-negative, genotype D-naive patients
por: Al-Ashgar, Hamad I., et al.
Publicado: (2011)

High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial
por: Alexander, George, et al.
Publicado: (2005)

Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance
por: Kim, Saein, et al.
Publicado: (2021)

Study on Post-Treatment Relapse in HBeAg Positive CHB Patients
por: Lu, Junfeng, et al.
Publicado: (2015)

The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics
por: Kramvis, Anna
Publicado: (2016)

Characteristics of an Outpatient Cohort with HBeAg-Negative Chronic Hepatitis B
por: Dimzova, Marija, et al.
Publicado: (2019)

The Complex Role of HBeAg and Its Precursors in the Pathway to Hepatocellular Carcinoma
por: Padarath, Kiyasha, et al.
Publicado: (2023)

A cautionary note to hepatitis B e antigen (HBeAg)‐negative test results in pregnant women in an area prevalent of HBeAg‐negative chronic hepatitis B
por: Chalid, Maisuri T., et al.
Publicado: (2022)

52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B
por: Piratvisuth, Teerha, et al.
Publicado: (2013)

HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis
por: Xing, Tongjing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q8ce4e6ja7c421riaebtg0gq6m